1 Segatto M, Leboffe L, Trapani L, Pallottini V (2014) Cholesterol Homeostasis Failure in the Brain: Implications for Synaptic Dysfunction and Cognitive Decline. Curr Med Chem [Epub ahead of print].

2Repa JJ, Lund EG, Horton JD, Leitersdorf E, Russell DW, et al. (2000) Disruption of the sterol 27-hydroxylase gene in mice results in hepatomegaly and hypertriglyceridemia. Reversal by cholic acid feeding. J Biol Chem 275: 39685-92.

3Dietschy JM, Turley SD (2004) Thematic review series: brain Lipids. Cholesterol metabolism in the central nervous system during early development and in the mature animal. J Lipid Res 45: 1375-97.

4Burger K, Gimpl G, Fahrenholz F (2000) Regulation of receptor function by cholesterol. Cell Mol Life Sci 57: 1577-92.

5 Weibel GL, Drazul-Schrader D, Shivers DK, Wade AN, Rothblat GH, et al. (2014) Importance of evaluating cell cholesterol influx with efflux in determining the impact of human serum on cholesterol metabolism and atherosclerosis. Arterioscler Thromb Vasc Biol 34: 17-25.

6 Tso P, Drake DS, Black DD, Sabesin SM (1984) Evidence for separate pathways of chylomicron and very low-density lipoprotein assembly and transport by rat small intestine. Am J Physiol 247: G599-610.

7D B Zilversmit (1965) The composition and structure of lymph chylomicrons in dog, rat, and man. J Clin Invest 44: 1610–22.

8Ockner RK, Manning JA (1974) Fatty acid-binding protein in small intestine. Identification, isolation, and evidence for its role in cellular fatty acid transport. J Clin Invest 54: 326-38.

9Zannis VI, Chroni A, Kypreos KE, Kan HY, Cesar TB, et al. (2004) Probing the pathways of chylomicron and HDL metabolism using adenovirus-mediated gene transfer. Curr Opin Lipidol 15: 151-66.

10Martini C, Pallottini V (2007) Cholesterol: from feeding to gene regulation. Genes Nutr 2: 181-93.

11 Dietschy JM (1984) Regulation of cholesterol metabolism in man and in other species. Klin Wochenschr 62: 338-45.

12Goldstein JL, Brown MS (1990) Regulation of the mevalonate pathway. Nature 343: 425-30.

13 Rozman D, Monostory K (2010) Perspectives of the non-statin hypolipidemic agents. Pharmacol Ther 127: 19-40.

14Ingebritsen TS (1983) Protein phosphorylation and the hormonal control of hepatic cholesterol synthesis. Biochem Soc Trans 11: 644-6.

15Xu F, Rychnovsky SD, Belani JD, Hobbs HH, Cohen JC, et al. (2005) Dual roles for cholesterol in mammalian cells. Proc Natl Acad Sci U S A 102: 14551-6.

16Espenshade PJ, Hughes AL (2007) Regulation of sterol synthesis in eukaryotes. Annu Rev Genet 41: 401-27.

17 Horton JD, Goldstein JL, Brown MS (2002) SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 109: 1125-31.

18 Sever N, Yang T, Brown MS, Goldstein JL, DeBose-Boyd RA (2003) Accelerated degradation of HMG CoA reductase mediated by binding of insig-1 to itsbsterol-sensing domain. Mol Cell 11: 25-33.

19Boekholdt SM, Arsenault BJ, Hovingh GK, Mora S, Pedersen TR, et al. (2013) Levels and changes of HDL cholesterol and apolipoprotein A-I in relation to risk of cardiovascular events among statin-treated patients: a meta-analysis. Circulation 128: 1504-12.

20Istvan ES, Deisenhofer J (2001) Structural mechanism for statin inhibition of HMG-CoA reductase. Science 292: 1160-4.

21 Orth M, Bellosta S (2012) Cholesterol: its regulation and role in central nervous system disorders. Cholesterol 2012: 292598

22 Allen JA, Halverson-Tamboli RA, Rasenick MM (2006) Lipid raft microdomains and neurotransmitter signalling. Nat Rev Neurosci 8: 128-40.

23 Sooksawate T, Simmonds MA (2001) Effects of membrane cholesterol on the sensitivity of the GABA(A) receptor to GABA in acutely dissociated rat hippocampal neurones. Neuropharmacology 40: 178-84.

24 Hering H, Lin CC, Sheng M (2003) Lipid rafts in the maintenance of synapses, dendritic spines, and surface AMPA receptor stability. J Neurosci 23: 3262-71.

25 Deutsch JW, Kelly RB (1981) Lipids of synaptic vesicles: relevance to the mechanism of membrane fusion. Biochemistry 20: 378-85.

26 Renkin EM (1977) Multiple pathways of capillary permeability. Circ Res 41: 735-43.

27 Rubin LL, Staddon JM (1999) The cell biology of the blood-brain barrier. Annu Rev Neurosci 22: 11-28.

28 Saito M, Benson EP, Saito M, Rosenberg A (1987) Metabolism of cholesterol and triacylglycerol in cultured chick neuronal cells, glial cells, and fibroblasts: accumulation of esterified cholesterol in serum-free culture. J Neurosci Res 18: 319-25.

29Segatto M, Di Giovanni A, Marino M, Pallottini V (2013) Analysis of the protein network of cholesterol homeostasis in different brain regions: an age and sex dependent perspective. J Cell Physiol 228: 1561-7.

30Segatto M, Trapani L, Lecis C, Pallottini V (2012) Regulation of cholesterol biosynthetic pathway in different regions of the rat central nervous system. Acta Physiol (Oxf) 206: 62-71.

31Pfrieger FW (2003) Outsourcing in the brain: do neurons depend on cholesterol delivery by astrocytes? Bioessays 25: 72-8.

32 Slezak M, Pfrieger FW (2003) New roles for astrocytes: regulation of CNS synaptogenesis. Trends Neurosci 26: 531-5.

33 Nieweg K, Schaller H, Pfrieger FW (2009) Marked differences in cholesterol synthesis between neurons and glial cells from postnatal rats. J Neurochem 109: 125-34.

34 Valenza M, Cattaneo E (2011) Emerging roles for cholesterol in Huntington's disease. Trends Neurosci 34: 474-86.

35 Bjorkhem I, Meaney S (2004) Brain cholesterol: long secret life behind a barrier. Arterioscler Thromb Vasc Biol 24: 806-15.

36 Oram JF, Heinecke JW (2005) ATP-binding cassette transporter A1: a cell cholesterol exporter that protects against cardiovascular disease. Physiol Rev 85: 1343-72.

37 Wang Z, Li DD, Liang YY, Wang DS, Cai NS (2002) Activation of astrocytes by advanced glycation end products: cytokines induction and nitric oxide release. Acta Pharmacol Sin 23: 974-80.

38 Hashimoto M, Rockenstein E, Crews L, Masliah E (2003) Role of protein aggregation in mitochondrial dysfunction and neurodegeneration in Alzheimer's and Parkinson's diseases. Neuromolecular Med 4: 21-36.

39 McIntire LB, Berman DE, Myaeng J, Staniszewski A, Arancio O, et al. (2011) Reduction of synaptojanin 1 ameliorates synaptic and behavioral impairments in a mouse model of Alzheimer's disease. J Neurosci 32: 15271-6.

40Cordy JM, Hussain I, Dingwall C, Hooper NM, Turner AJ (2003) Exclusively targeting beta-secretase to lipid rafts by GPI-anchor addition up-regulates beta-site processing of the amyloid precursor protein. Proc Natl Acad Sci U S A 100: 11735-40.

41 Xiong H, Callaghan D, Jones A, Walker DG, Lue LF, et al. (2008)Cholesterol retention in Alzheimer's brain is responsible for high beta- and gamma-secretase activities and Abeta production. Neurobiol Dis 29: 422-37.

42Bryleva EY, Rogers MA, Chang CC, Buen F, Harris BT, et al. (2010) ACAT1 gene ablation increases 24(S)-hydroxycholesterol content in the brain and ameliorates amyloid pathology in mice with AD. Proc Natl Acad Sci U S A 107: 3081-6.

43Blennow K, de Leon MJ, Zetterberg H (2006) Alzheimer's disease. Lancet 368: 387-403.

44Wolozin B (2004) Cholesterol and the biology of Alzheimer's disease. Neuron 41: 7-10.

45Trommer BL, Shah C, Yun SH, Gamkrelidze G, Pasternak ES, et al. (2004) ApoE isoform affects LTP in human targeted replacement mice. Neuroreport 15: 2655-8.

46Levi O, Jongen-Relo AL, Feldon J, Roses AD, Michaelson DM (2003) ApoE4 impairs hippocampal plasticity isoform-specifically and blocks the environmental stimulation of synaptogenesis and memory. Neurobiol Dis 13: 273-82.

47 Wang C, Wilson WA, Moore SD, Mace BE, Maeda N, et al. (2005) Human apoE4-targeted replacement mice display synaptic deficits in the absence of neuropathology. Neurobiol Dis 18: 390-8.

48Zhong N, Scearce-Levie K, Ramaswamy G, Weisgraber KH (2008) Apolipoprotein E4 domain interaction: synaptic and cognitive deficits in mice. Alzheimers Dement 4: 179-92.

49Izaks GJ, Gansevoort RT, van der Knaap AM, Navis G, Dullaart RP, et al. (2011) The association of APOE genotype with cognitive function in persons aged 35 years or older. PLoS One 6: e27415.

50Desai P, DeKosky ST, Kamboh MI (2002) Genetic variation in the cholesterol 24-hydroxylase (CYP46) gene and the risk of Alzheimer's disease. Neurosci Lett 328: 9-12.

51Kolsch H, Lutjohann D, Ludwig M, Schulte A, Ptok U, et al. (2002) Polymorphism in the cholesterol 24S-hydroxylase gene is associated with Alzheimer's disease. Mol Psychiatry 7: 899-902.

52Wollmer MA, Streffer JR, Lutjohann D, Tsolaki M, Iakovidou V, et al. (2003) ABCA1 modulates CSF cholesterol levels and influences the age at onset of Alzheimer's disease. Neurobiol Aging 24: 421-6.

53 Puglielli L, Konopka G, Pack-Chung E, Ingano LA, Berezovska O, et al. (2001) Acyl-coenzyme A: cholesterol acyltransferase modulates the generation of the amyloid beta-peptide. Nat Cell Biol 3: 905-12.

54 Sun Y, Yao J, Kim TW, Tall AR (2003) Expression of liver X receptor target genes decreases cellular amyloid beta peptide secretion. J Biol Chem 278: 27688-94.

55Kojro E, Gimpl G, Lammich S, Marz W, Fahrenholz F (2001) Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha -secretase ADAM 10. Proc Natl Acad Sci U S A 98: 5815-20.

56Buxbaum JD, Geoghagen NS, Friedhoff LT (2001) Cholesterol depletion with physiological concentrations of a statin decreases the formation of the Alzheimer amyloid Abeta peptide. J Alzheimers Dis 3: 221-9.

57 Chauhan N, Wang KC, Wegiel J, Malik MN (2004) Walnut extract inhibits the fibrillization of amyloid beta-protein, and also defibrillizes its preformed fibrils. Curr Alzheimer Res 1: 183-8.

58Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA (2000) Statins and the risk of dementia. Lancet 356: 1627-31.

59Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G (2000) Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol 57: 1439-43.

60Simons K, Ehehalt R (2002) Cholesterol, lipid rafts, and disease. J Clin Invest 110: 597-603.

61Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, et al. (2002) Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360: 1623-30.

62Vanier MT, Millat G (2003) Niemann-Pick disease type C. Clin Genet 64: 269-81.

63Sevin M, Lesca G, Baumann N, Millat G, Lyon-Caen O, et al. (2007) The adult form of Niemann-Pick disease type C. Brain 130: 120-33.

64Vanier MT, Millat G (2004) Structure and function of the NPC2 protein. Biochim Biophys Acta 1685: 14-21.

65Vazquez MC, Balboa E, Alvarez AR, Zanlungo S (2012) Oxidative stress: a pathogenic mechanism for Niemann-Pick type C disease. Oxid Med Cell Longev 2012: 205713.

66Sun X, Marks DL, Park WD, Wheatley CL, Puri V, et al. (2001) Niemann-Pick C variant detection by altered sphingolipid trafficking and correlation with mutations within a specific domain of NPC1. Am J Hum Genet 68: 1361-72.

67Tang Y, Li H, Liu JP (2010) Niemann-Pick Disease Type C: From molecule to clinic. Clin Exp Pharmacol Physiol 37: 132-40.

68 Patterson MC (2003) A riddle wrapped in a mystery: Understanding Niemann-Pick disease, type C. Neurologist 9: 301-10.

69Liu B, Ramirez CM, Miller AM, Repa JJ, Turley SD, et al. (2010) Cyclodextrin overcomes the transport defect in nearly every organ of NPC1 mice leading to excretion of sequestered cholesterol as bile acid. J Lipid Res 51: 933-44.

70Ribas GS, Pires R, Coelho JC, Rodrigues D, Mescka CP, et al. (2012) Oxidative stress in Niemann-Pick type C patients: a protective role of N-butyl-deoxynojirimycin therapy. Int J Dev Neurosci 30: 439-44.

71 Landles C, Bates GP (2004) Huntingtin and the molecular pathogenesis of Huntington's disease. Fourth in molecular medicine review series. EMBO Rep 5: 958-63.

72Ross CA, Tabrizi SJ (2011) Huntington's disease: from molecular pathogenesis to clinical treatment. Lancet Neurol 10: 83-98.

73 Harjes P, Wanker EE (2003) The hunt for huntingtin function: interaction partners tell many different stories. Trends Biochem Sci 28: 425-33

74Rigamonti D, Bauer JH, De-Fraja C, Conti L, Sipione S, et al. (2000) Wild-type huntingtin protects from apoptosis upstream of caspase-3. J Neurosci 20: 3705-13.

75Sipione S, Rigamonti D, Valenza M, Zuccato C, Conti L, et al. (2002) Early transcriptional profiles in huntingtin-inducible striatal cells by microarray analyses. Hum Mol Genet 11: 1953-65.

76 Valenza M, Leoni V, Karasinska JM, Petricca L, Fan J, et al. (2010) Cholesterol defect is marked across multiple rodent models of Huntington's disease and is manifest in astrocytes. J Neurosci 30: 10844-50.

77Valenza M, Carroll JB, Leoni V, Bertram LN, Bjorkhem I, et al. (2007) Cholesterol biosynthesis pathway is disturbed in YAC128 mice and is modulated by huntingtin mutation. Hum Mol Genet 16: 2187-98.

78 Valenza M, Rigamonti D, Goffredo D, Zuccato C, Fenu S, et al. (2005) Dysfunction of the cholesterol biosynthetic pathway in Huntington's disease. J Neurosci 25: 9932-9.

79Okamoto K, Kakuma T, Fukuchi S, Masaki T, Sakata T, et al. (2006) Sterol regulatory element binding protein (SREBP)-1 expression in brain is affected by age but not by hormones or metabolic changes. Brain Res 1081: 19-27.

80 Valenza F, Aletti G, Fossali T, Chevallard G, Sacconi F, et al. (2005) Lactate as a marker of energy failure in critically ill patients: hypothesis. Crit Care 9: 588-93.

81 Del Toro D, Xifro X, Pol A, Humbert S, Saudou F, et al. (2011) Altered cholesterol homeostasis contributes to enhanced excitotoxicity in Huntington's disease. J Neurochem 115: 153-67.

82 Leoni V, Mariotti C, Tabrizi SJ, Valenza M, Wild EJ, et al. (2008) Plasma 24S-hydroxycholesterol and caudate MRI in pre-manifest and early Huntington's disease. Brain 131: 2851-9.

83 Block RC, Dorsey ER, Beck CA, Brenna JT, Shoulson I (2010) Altered cholesterol and fatty acid metabolism in Huntington disease. J Clin Lipidol 4: 17-23.

84 Muhle R, Trentacoste SV, Rapin I (2004) The genetics of autism. Pediatrics. 113: e472-86.

85 Merkens LS, Wassif C, Healy K, Pappu AS, DeBarber AE, et al. (2009) Smith-Lemli-Opitz syndrome and inborn errors of cholesterol synthesis: summary of the 2007 SLO/RSH Foundation scientific conference sponsored by the National Institutes of Health. Genet Med 11: 359-64.

86 Porter FD (2008)< Smith-Lemli-Opitz syndrome: pathogenesis, diagnosis and management. Eur J Hum Genet 16: 535-41.

87DeBarber AE, Eroglu Y, Merkens LS, Pappu AS, Steiner RD (2011) Smith-Lemli-Opitz syndrome. Expert Rev Mol Med 13: e24.

88Fliesler SJ (2013) Antioxidants: the missing key to improved therapeutic intervention in Smith-Lemli-Opitz syndrome? Hereditary Genet 2: 119.

89 Nowaczyk MJ, Irons MB (2012) Smith-Lemli-Opitz syndrome: phenotype, natural history,and epidemiology. Am J Med Genet C Semin Med Genet 160C: 250- 62.

90Diaz-Stransky A, Tierney E (2012) Cognitive and behavioral aspects of Smith-Lemli-Opitz syndrome. Am J Med Genet C Semin Med Genet 160C: 295-300.

91 Mueller C, Patel S, Irons M, Antshel K, Salen G, et al. (2003) Normal cognition and behavior in a Smith-Lemli-Opitz syndrome patient who presented with Hirschsprung disease. Am J Med Genet A 123A: 100-6.

92 Sikora DM, Pettit-Kekel K, Penfield J, Merkens LS, Steiner RD (2006) The near universal presence of autism spectrum disorders in children with Smith-Lemli- Opitz syndrome. Am J Med Genet Al 140: 1511-8.

93Aneja A, Tierney E (2008) Autism: the role of cholesterol in treatment. Int Rev Psychiatry 20: 165-70.

94 Tierney E, Bukelis I, Thompson RE, Ahmed K, Aneja A, et al. (2006) Abnormalities of cholesterol metabolism in autism spectrum disorders. Am J Med Genet B Neuropsychiatr Genet 141B: 666-8.

95Dziobek I, Gold SM, Wolf OT, Convit A (2007) Hypercholesterolemia in Asperger syndrome: independence from lifestyle, obsessive-compulsive behavior, and social anxiety. Psychiatry Res 149: 321-4.

96 Macdonald JL, Verster A, Berndt A, Roskams AJ (2010) MBD2 and MeCP2 regulate distinct transitions in the stage-specific differentiation of olfactory receptor neurons. Mol Cell Neurosci 44: 55-67

97 Buchovecky CM, Turley SD, Brown HM, Kyle SM, McDonald JG, et al. (2013) A suppressor screen in Mecp2 mutant mice implicates cholesterol metabolism in Rett syndrome. Nat Genet 45: 1013-20.

98 Sticozzi C, Belmonte G, Pecorelli A, Cervellati F, Leoncini S, et al. (2013) Scavenger receptor B1 post-translational modifications in Rett syndrome. FEBS Lett 587: 2199-204.

99 De Berardis D, Conti CM, Serroni N, Moschetta FS, Carano A, et al. (2009) The role of cholesterol levels in mood disorders and suicide. J Biol Regul Homeost Agents 23: 133-40.

100 Morgan RE, Palinkas LA, Barrett-Connor EL, Wingard DL (1993) Plasma cholesterol and depressive symptoms in older men. Lancet 341: 75–9.

101 Maes M, Delanghe J, Meltzer HY, Scharpé S, D'Hondt P, et al. (1994) Lower degree of esterification of serum cholesterol in depression: relevance for depression and suicide research. Acta Psychiatr Scan 90: 252–8.

102Rafter D (2001) Biochemical markers of anxiety and depression. Psychiatry Res 103: 93–6.

103 Lieberman HR, Kellogg MD, Kramer FM, Bathalon GP, Lesher LL (2012) Lipid and other plasma markers are associated with anxiety, depression, and fatigue. Health Psychol 31: 210-6.

104Rabe-Jablonska J, Poprawska I (2000) Levels of serum total cholesterol and LDL-cholesterol in patients with major depression in acute period and remission. Med Sci Monit 6: 539–47.

105Steegmans PH, Hoes AW, Bak AA, Van der Does E, Grobbee DE (2004) Higher prevalence of depressive symptoms in middle-aged men with low serum cholesterol levels. Psychosom Med 62: 205–11.

106Horsten M, Wamala SP, Vingerhoets A, Orth-Gomer K (1997) Depressive symptoms, social support, and lipid profile in healthy middle-aged women. Psychosom Med 59: 521–8.

107 You H, Lu W, Zhao S, Hu Z, Zhang J (2013) The relationship between statins and depression: a review of the literature. Expert Opin Pharmacother 14: 1467-76.

108Tatley M, Savage R (2007) Psychiatric adverse reactions with statins, fibrates and ezetimibe: implications for the use of lipid-lowering agents. Drug Saf 30: 195-201.

109Maes M, Smith R, Christophe A, Vandooleaghe E, Van Gastel A, et al. (1997) Lower serum high-density lipoprotein cholesterol (HDL-C) in major depression and in depressed men with serious suicidal attempts: relationship with immune-inflammatory markers. Acta Psychiatr Scand 95: 212–21.

110 Papadopoulou A, Markianos M, Christodoulou C, Lykouras L (2013) Plasma total cholesterol in psychiatric patients after a suicide attempt and in follow-up. J Affect Disord 148: 440-3.

111Atmaca M, Kuloglu M, Tezcan E, Ustundag B, Gecici O, et al. (2002) Serum leptin and cholesterol values in suicide attempters. Neuropsychobiology 45: 124–7.

112Olié E, Picot MC, Guillaume S, Abbar M, Courtet P (2011) Measurement of total serum cholesterol in the evaluation of suicidal risk. J Affect Disord 133: 234-8.

113Kim YK, Lee HJ, Yoon DK, Choi SH, et al. (2002) Low serum cholesterol is correlated to suicidality in a Korean sample. Acta Psychiatr Scand 105: 141–8.

114Ruljancic N, Mihanovic M, Cepelak I (2011) Thrombocyte serotonin and serum cholesterol concentration in suicidal and non-suicidal depressed patients. Prog Neuropsychopharmacol Biol Psychiatry 35: 1261-7.

115Lütjohann D (2007) Brain cholesterol and suicidal behaviour. Int J Neuropsychopharmacol 10: 153-7.

116 Beasley CL, Honer WG, Bergmann K, Falkai P, Lütjohann D, et al. (2005) Reductions in cholesterol and synaptic markers in association cortex in mood disorders. Bipolar Disord 7: 449-55.

117Lalovic A, Levy E, Luheshi G, Canetti L, Grenier E, et al. (2007) Cholesterol content in brains of suicide completers. Int J Neuropsychopharmacol 10: 159-66.

118Lalovic A, Merkens L, Russell L, Arsenault-Lapierre G, Nowaczyk MJ, et al. (2004) Cholesterol metabolism and suicidality in Smith-Lemli-Opitz syndrome carriers. Am J Psychiatry 161: 2123-6.

119Freedman DS, Byers T, Barrett DH, Stroup NE, Eaker E, et al. (1995) Plasma lipid levels and psychologic characteristics in men. Am J Epidemiol 141: 507–17.

120McCallum J, Simons L, Simons J, Friedlander Y (1994) Low serum cholesterol is not associated with depression in the elderly: data from an Australian community study. Aust NZ J Med 24: 561–4.

121 Jakovljević M, Reiner Z, Milicić D (2007) Mental disorders, treatment response, mortality and serum cholesterol: a new holistic look at old data. Psychiatr Danub 19: 270-81.

122Bajwa WK, Asnis GM, Sanderson WC, Irfan A, van Praag HM (1992) High cholesterol levels in patients with panic disorder. Am J Psychiatry 149: 376–8.

123Kagan BL, Leskin G, Haas B,Wilkins J, Foy D (1999) Elevated lipid levels in Vietnam veterans with chronic posttraumatic stress disorder. Biol Pscyhiatry 45: 374–7.

124Peter H, Hand I, Hohagen F, Koenig A, Mindermann O, et al. (2002) Serum cholesterol level comparison: control subjects, anxiety disorder patients, and obsessive-compulsive disorder patients. Can J Psychiatry 47: 557–61.

125Suarez EC (1999) Relations of trait depression and anxiety to low lipid and lipoprotein concentrations in healthy young adult women. Psychosom Med 61: 273–9.

126Segatto M, Manduca A, Lecis C, Rosso P, Jozwiak A, et al. (2014) Simvastatin treatment highlights a new role for the isoprenoid/cholesterol biosynthetic pathway in the modulation of emotional reactivity and cognitive performance in rats. Neuropsychopharmacology 39: 841-54.

127Thomas JM, Varkey J, Augustine BB (2014) Association between serum cholesterol, brain serotonin, and anxiety: A study in simvastatin administered experimental animals. Int J Nutr Pharmacol Neurol Dis 4: 69-73.

128Golomb BA (1998) Cholesterol and violence: is there a connection? Ann Intern Med 128: 478-87.

129 Hillbrand M, reuben TS (1999) Cholesterol and aggression. Aggression and Violent Behav 4: 359-70.

130Richards JC, Hof A, Alvarenga M (2000) Serum lipids and their relationships with hostility and angry affect and behaviors in men. Health Psychol 19: 393-8.

131Troisi A (2009) Cholesterol in coronary heart disease and psychiatric disorders: same or opposite effects on morbidity risk? Neurosci Biobehav Rev 33: 125-32.

132Saleem S, Haider S, Naqvi F, Tabassum S, Haleem DJ (2011) Long term administration of hmg-coa-reductase inhibitor (simvastatin) affects brain serotonin neurotransmission in male rats. Int J Basic Appl Sci 7: 79-83.

133Scanlon SM, Williams DC, Schloss P (2001) Membrane cholesterol modulates serotonin transporter activity. Biochemistry 40: 10507-13.

134 Jafurulla M, Rao BD, Sreedevi S, Ruysschaert JM, Covey DF, et al. (2014) Stereospecific requirement of cholesterol in the function of the serotonin1A receptor. Biochim Biophys Acta 1838: 158-63.

135 Fassbender K, Simons M, Bergmann C, Stroick M, Lutjohann D, et al. (2001) Simvastatin strongly reduces levels of Alzheimer's disease beta -amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc Natl Acad Sci U S A 98: 5856-61.

136 Simons M, Keller P, De Strooper B, Beyreuther K, Dotti CG, et al. (1998) Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc Natl Acad Sci U S A. 95: 6460-4.

137 Heverin M, Bogdanovic N, Lütjohann D, Bayer T, Pikuleva I, et al. (2004) Changes in the levels of cerebral and extracerebral sterols in the brain of patients with Alzheimer's disease. J Lipid Res 45: 186-93.

138Cedazo-Mínguez A, Ismail MA, Mateos L (2011) Plasma cholesterol and risk for late-onset Alzheimer's disease. Expert Rev Neurother 11: 495-8.

139 Distl R, Treiber-Held S, Albert F, Meske V, Harzer K, et al. (2003) Cholesterol storage and tau pathology in Niemann-Pick type C disease in the brain. J Pathol 200: 104-11.

140 Reid PC, Sakashita N, Sugii S, Ohno-Iwashita Y, Shimada Y, et al. (2004) A novel cholesterol stain reveals early neuronal cholesterol accumulation in the Niemann-Pick type C1 mouse brain. J Lipid Res 45: 582-91.

141 Fitzky BU, Moebius FF, Asaoka H, Waage-Baudet H, Xu L, et al. (2001) 7-Dehydrocholesterol-dependent proteolysis of HMG-CoA reductase suppresses sterol biosynthesis in a mouse model of Smith-Lemli-Opitz/RSH syndrome. J Clin Invest 108: 905-15.

142 Tint GS, Seller M, Hughes-Benzie R, Batta AK, Shefer S, et al. (1995) Markedly increased tissue concentrations of 7-dehydrocholesterol combined with low levels of cholesterol are characteristic of the Smith-Lemli-Opitz syndrome. J Lipid Res 36: 89-95.